Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

A Pill to Shed Fat?

December 8, 2014 2:36 pm | by B.D. Colen, Harvard University | News | Comments

Researchers created a system using human stem cells to screen for compounds that have the potential to turn white fat cells into brown fat cells. Read more...             


Tasigna Wins Over Gleevec in Ph+CML Patients

December 8, 2014 1:45 pm | News | Comments

Six-year results from Novartis' randomized Phase 3 study continue to demonstrate the superiority of Tasigna compared to Glivec. Read more...                   


New Agent Shrinks Small Cell Lung Tumors in Pre-Clinical Testing

December 8, 2014 1:20 pm | News | Comments

Researchers found that a new agent can disable the basic part of a tumor cell's survival mechanism. Read more...                         


New Immunotherapy Breakthrough Discovered

December 8, 2014 1:06 pm | by Robert Levy, Harvard Medical School | News | Comments

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma into complete or partial remission. Read more...                     


FDA Approves Amgen's Hypercalcemia Drug

December 8, 2014 12:53 pm | News | Comments

The FDA approved Amgen's drug that treats hypercalcemia. Read more...                                


Pfizer Expands Rare Disease Research with Gene Therapy Platform

December 8, 2014 12:34 pm | News | Comments

Pfizer announced two strategic decisions to expand the company’s rare disease research and development activities. Read more...                       


Merck Buys Cubist Pharmaceuticals for $8.4B

December 8, 2014 12:27 pm | by Tom Murphy - AP Business Writer | News | Comments

Merck will spend $8.4 billion to buy Cubist Pharmaceuticals. Read more...                                


Journal Watch: Tamoxifen in the News Again

December 8, 2014 11:57 am | by Drug Discovery & Development Staff | Articles | Comments

Tamoxifen, the leading estrogen blocker, has done so well by hormone receptor-positive breast cancer patients that the American Society for Clinical Oncology (ASCO) changed its guidelines this year, advising certain patients to take the drug for ten years instead of five. Read more...


BioDelivery Sciences: Phase 3 Trial of Diabetic Neuropathy Topical Gel

December 8, 2014 10:52 am | News | Comments

BioDelivery Sciences International, Inc. announced that it has completed the randomization of all patients in BDSI's ongoing initial pivotal Phase 3 clinical trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). Read more...


Norovirus Sickens 200 People on New Zealand Cruise

December 8, 2014 10:41 am | by Associated Press | News | Comments

Health authorities in New Zealand said that about 200 passengers on a cruise ship have been sickened by an outbreak of norovirus. Read more...                                                    


Breakthrough in Fibrosis Research

December 8, 2014 10:33 am | by University of Bath, UK | News | Comments

Researchers from the Departments of Pharmacy & Pharmacology and Biology & Biochemistry have made an important discovery that might lead to novel therapies to combat chronic fibrotic diseases. Read more...                          


Amgen, Onyx: Phase 3 Study Results in Myeloma Trial

December 8, 2014 10:26 am | News | Comments

Amgen and its subsidiary Onyx results of the Phase 3 ASPIRE trial, which evaluated Kyprolis (carfilzomib) for Injection plus Revlimid (lenalidomide) and dexamethasone (KRd) compared with Revlimid and dexamethasone (Rd) in patients with relapsed multiple myeloma. Read more...


Seattle Genetics, Takeda: Clinical Trial Data in HL Patients

December 8, 2014 10:17 am | News | Comments

Seattle Genetics, Inc. and Takeda reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse following an autologous stem cell transplant (ASCT) who received Adcetris (brentuximab vedotin) as consolidation therapy immediately after ASCT had significant improvement in progression-free survival (PFS) compared to patients who received placebo (median of 43 months versus 24 months, respectively. Read more...


VIDEO: Drug Development in a Time of Ebola

December 8, 2014 10:04 am | by Ryan Bushey, Associate Editor | Videos | Comments

This video from the Forbes Healthcare Summit focuses on the drug development process during a time of ebola. Watch it here...                       


Merck's Cancer Therapy Receives Positive Results

December 8, 2014 10:03 am | News | Comments

Merck announced early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.